Skip to main content
OpenTrials

Clinical trial condition

Hypersensitivity, Immediate

Explore clinical trials studying Hypersensitivity, Immediate. Study availability and eligibility vary by location and protocol.

6,714 public trials 622 recruiting studies
Refine in advanced search Browse all conditions

Hypersensitivity, Immediate trial results

Completed

Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab

NCT06806657

Conditions
Angioedema, Angioedemas, Hereditary, Cardiovascular Diseases, +14 more
Locations
  • Research Solutions of Arizona Litchfield Park, Arizona, United States
  • Allergy and Asthma Clinic of Northwest Arkansas Bentonville, Arkansas, United States
  • Donald Levy M.D. Orange, California, United States
  • Raffi Tachdjian MD, Inc. Santa Monica, California, United States
View Trial Details
Completed

A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)

NCT05899816

Conditions
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, +10 more
Locations
  • Affiliated Dermatology Scottsdale, Arizona, United States
  • Center for Dermatology and Plastic Surgery Scottsdale, Arizona, United States
  • Scottsdale Clinical Trials Scottsdale, Arizona, United States
  • Medical Advancement Centers of Arizona Tempe, Arizona, United States
View all 85 locations
View Trial Details
Completed

A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)

NCT05398445

Conditions
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, +9 more
Locations
  • Cahaba Dermatology and Skin Health Center Birmingham, Alabama, United States
  • Alliance Dermatology and Mohs Center Phoenix, Arizona, United States
  • Anaheim Clinical Trials Anaheim, California, United States
  • First OC Dermatology Fountain Valley, California, United States
View all 202 locations
View Trial Details
Completed

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

NCT06130566

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, Dermatitis Atopic, +9 more
Locations
  • Scottsdale Clinical Trials- Site Number : 8401149 Scottsdale, Arizona, United States
  • First OC Dermatology- Site Number : 8401025 Fountain Valley, California, United States
  • Center for Dermatology Clinical Research- Site Number : 8401018 Fremont, California, United States
  • Sunwise Clinical Research- Site Number : 8401022 Lafayette, California, United States
View all 148 locations
View Trial Details
Completed

A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)

NCT05277571

Conditions
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, +9 more
Locations
  • Up0110 125 Beverly Hills, California, United States
  • Up0110 101 Glendale, California, United States
  • Up0110 116 Los Angeles, California, United States
  • Up0110 121 Northridge, California, United States
View all 16 locations
View Trial Details
Completed

Description of Characteristics, Such as Age, Previous and Concurrent Treatments, Associated Diseases, of Patients With Asthma Treated With Dupilumab (DUPIXENT)

NCT04550962

Conditions
Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations
  • Investigational Site Number : 0320005 La Plata, Buenos Aires, Argentina
  • Investigational Site Number : 0320006 Villa Rosa, Buenos Aires, Argentina
  • Investigational Site Number : 0320001 Ciudad Autonoma Bs As, Argentina
  • Investigational Site Number : 0320008 Ciudad Autonoma Buenos Aires, Argentina
View all 41 locations
View Trial Details
Completed

A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid

NCT05292586

Conditions
Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations
  • Chiesi Clinical Trial Site 840858 Mobile, Alabama, United States
  • Chiesi Clinical Trial Site 840895 Chandler, Arizona, United States
  • Chiesi Clinical Trial Site 840856 Encinitas, California, United States
  • Chiesi Clinical Trial Site 840843 Huntington Beach, California, United States
View all 91 locations
View Trial Details

Related conditions